{"id":"W2255227919","doi":"10.1200/jco.2013.31.15_suppl.8027","title":"Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for <i>KRAS</i>-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pemetrexed; Trametinib; KRAS; Internal medicine; Lung cancer; Tolerability; Oncology; Response Evaluation Criteria in Solid Tumors; MEK inhibitor; Adverse effect; Cancer; Phases of clinical research; Chemotherapy; Gastroenterology; Colorectal cancer; Cisplatin; Kinase; MAPK/ERK pathway","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008750678,0.001052596,0.001128956,0.0003405047,0.0002304826,0.0007134376,0.0006615408,0.0008591817,0.003368794],"category_scores_gemma":[0.0004373911,0.0005463603,0.0007669912,0.0003374397,0.0005396368,0.0006662481,0.0003044821,0.001973078,0.0008344281],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006127449,"about_ca_system_score_gemma":0.0009961592,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000832747,"about_ca_topic_score_gemma":0.002998444,"domain_scores_codex":[0.9998094,0.0000893927,0.0000128317,0.00002844873,0.00001965443,0.00004025849],"domain_scores_gemma":[0.9997602,0.00003607882,0.00005666887,0.00001518369,0.00001186674,0.0001200197],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.78706,0.04016664,0.005207343,0.001583659,0.001489453,0.0002410395,0.0002104113,0.002561394,0.0479229,0.0002428318,0.004414623,0.1088997],"study_design_scores_gemma":[0.6733427,0.3072497,0.01038539,0.00006088959,0.0006466582,0.0003457779,0.00005450336,0.001240195,0.004102272,0.0001156958,0.002427845,0.00002832474],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992933,0.002274985,0.0002632234,0.0002827227,0.00006573911,0.001570659,0.0006788037,0.00009510181,0.001835805],"genre_scores_gemma":[0.9918704,0.001920677,0.0007844697,0.0004021851,0.00008388586,0.001301544,0.00149681,0.00001692791,0.002123132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003368794,"threshold_uncertainty_score":0.01126975,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05341897179698591,"score_gpt":0.4718817964688599,"score_spread":0.418462824671874,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}